
COOK COUNTY DEPARTMENT OF PUBLIC HEALTH
Influenza A (H1N1) Vaccine Post-test Training - Answers

The correct answer is italicized and bolded. The rationale follows the response.

1. There are four (4) H1N1 types of vaccine manufactured for use in the U.S.
 - a. ***True***
 - b. False

MedImmune, Sanofi-Pasteur, Novartis and CSL, are the four (4) manufacturers of H1N1 vaccine licensed for use in the U.S.

2. The Live Attenuated Intranasal Vaccine (LAIV-H1N1) is a weakened strain of the H1N1 virus and is intended for healthy people ages 2 – 49 years of age.
 - a. ***True***
 - b. False

LAIV-H1N1 is indicated for the active immunization of individuals 2 – 49 years of age against influenza disease caused by pandemic (H1N1) 2009 virus.

3. Active inhalation (i.e., sniffing) is required during administration of LAIV-H1N1.
 - a. True
 - b. ***False***

Package insert instructions state that active inhalation (i.e., sniffing) is not required by the patient during vaccine administration.

4. LAIV-H1N1 must be kept frozen until used.
 - a. True
 - b. ***False***

H1N1 vaccines are to be kept at 36° - 46° F, discard if frozen.

5. There is no preservative in the single dose preparations of H1N1 vaccine licensed for use in children < 4 years of age.
 - a. ***True***
 - b. False

LAIV-H1N1, Sanofi-Pasteur 0.25 mL pre-filled syringe, Sanofi-Pasteur 0.5mL pre-filled syringe and Sanofi-Pasteur 0.5 single-dose vial are preservative free and licensed for use in children < 4 years of age.

6. If a student has received an Influenza A (H1N1) vaccination in the past 28 days he/she will not be vaccinated by CCDPH.
 - a. ***True***
 - c. False

A second dose of H1N1 vaccine can only be given 28 days after the 1st vaccination.

7. Immunocompromised people should not receive LAIV-H1N1.
- a. **True**
 - b. False

LAIV-H1N1 is contraindicated in people with weakened immune system/immunocompromised from conditions such as HIV/AIDS, cancer, leukemia, lymphoma, lupus. Safety has not been established in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications.

8. If the person to be vaccinated has an illness with fever > 100° F or other active infection they will be vaccinated by CCDPH.
- a. True
 - b. **False**

Acute febrile illness or other active infection is a contraindication to receiving vaccination because the body is working to develop immunity to the disease that is causing the fever and infection.

9. Hypersensitivity to eggs or any component of the vaccine and/or a life threatening reaction to previous influenza vaccine is contraindications to receiving vaccination.
- a. **True**
 - b. False

H1N1 vaccine is prepared from influenza virus propagated in embryonated chicken eggs. An allergy or hypersensitivity to eggs could result in a life threatening reaction if the vaccine were administered to this individual.

10. Pregnant people, people younger than 2 years of age, people over the age of 50 and people with a history of asthma or active wheezing will not receive LAIV-H1N1.
- a. **True**
 - b. False

Do not administer LAIV-H1N1 to children < 24 months of age because of increased risk of hospitalization and wheezing. The vaccine is not licensed for use in people 50 years of age and older.

11. If the person to be vaccinated has received live virus vaccines like FluMist, MMR, or Varicella in the past 28 days they should not be vaccinated with LAIV-H1N1.
- a. **True**
 - b. False

Interference can occur between two (2) live vaccines given less than 28 days apart.

12. People with a weakened immune system which would make him/her more likely to contract an infection should be vaccinated with LAIV-H1N1.
- a. True
 - b. **False**

LAIV-H1N1 is contraindicated in people with weakened immune system/immunocompromised from conditions such as HIV/AIDS, cancer, leukemia, lymphoma, lupus. Safety has not been established in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications.

13. People < 18 years of age receiving Aspirin-containing therapy should receive LAIV-H1N1.
- a. True
 - b. False**

LAIV-H1N1 is contraindicated in individuals under the age of 18 who are on Aspirin-containing therapy. Due to the risk of developing Reye's syndrome, a deadly disease, which can affect all body organs, with the liver and brain suffering most seriously.

14. People allergic to gentamicin, gelatin, or arginine should not receive LAIV-H1N1.
- a. True**
 - b. False

Gentamicin, gelatin and arginine are components of LAIV-H1N1 vaccine.

15. Antiviral medications taken 48 hours prior to vaccination can lower or prevent the vaccinated person from responding to the vaccine and the person may not get immune protection from the vaccine.
- a. True**
 - b. False

Antiviral drugs taken from 48 hours before through 2 weeks after getting LAIV-HINI can lower or prevent the vaccinated person from responding to the vaccine and the person may not get immune protection from the vaccine.

16. People 6 months of age and older and people < 10 years of age need two (2) doses of H1N1 vaccine to confer immunity.
- a. True**
 - b. False

Children < 10 years of age need two (2) doses of vaccine to confer immunity.

17. People with a history of Guillain-Barre' syndrome (GBS) should receive H1N1 vaccine.
- a. True
 - b. False**

In 1976, vaccination with the swine flu vaccine was associated with development of GBS. GBS is an illness characterized by fever, nerve damage, and muscle weakness.

REFERENCES

- A. Vaccine Information Statement for 2009 H1N1 Influenza Vaccine (10/2/2009) located at <http://www.cdc.gov/vaccines/Pubs/vis/downloads/vis-laiv/h1n1.pdf>
- B. Vaccine Information Statement for 2009 H1N1 Influenza Vaccine (10/2/2009) located at <http://www.cdc.gov/h1n1flu/vaccination/slv/pdf/vis-h1n1-prelicensure.pdf>

- C. Package insert for Influenza A (H1N1) 2009 Monovalent, Vaccine Live, Intranasal Manufactured by MedImmune, LLC located at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182406.pdf>
- D. CCDPH Policy Standing Orders for Inactivated Influenza A (H1N1)Vaccine, Number 770-0929-09
- E. CCDPH Policy Public Health Physician Standing Order for Administration of Live Attenuated Influenza A (H1N1) Vaccine (LAIV-H1N1), Number 772-0929-09
- F. CCDPH Policy Guidelines for the Administration of Live Attenuated H1N1 Influenza Vaccine (LAIV-H1N1), Number 771-0929-09
- G. CCDPH Policy Guidelines for the Administration of Inactivated Influenza A (H1N1) Influenza Vaccine in CCDPH Clinics, Number 769-0929-09